Duvakitug in adults with moderate to severe hidradenitis suppurativa

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with three active dose groups and a placebo arm. Participants have at least 6 months of hidradenitis suppurativa with lesions in two distinct areas and a baseline abscess and inflammatory nodule count of 5 or more. The study uses a dose-ranging design over an initial 16-week double-blind period, followed by an active extension and a long-term extension, with follow-up up to 145 weeks total. Primary aims focus on safety and efficacy across multiple doses for adult HS patients who have not responded adequately to antibiotics or have intolerance to antibiotics. Investigators will monitor adverse events and treatment effects across diverse geographic sites educated by a multinational framework.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with a history of signs and symptoms consistent with hidradenitis suppurativa (HS) for at least 6 months prior to Baseline Visit
* Participants must have HS lesions present in at least 2 distinct anatomic areas (eg, left, and right axilla; or left axilla and left inguino-crural fold), with at least 1 body site being Hurley Stage II or III.
* Participant must have a total abscess and inflammatory nodule (AN) count of ≥5 at the Baseline Visit.
* Participants must have had an inadequate response to a course of a systemic antibiotics for treatment of HS, exhibited recurrence after discontinuation of antibiotics or demonstrated intolerance to antibiotics, or has a contraindication to systemic antibiotics for treatment of their HS as assessed by the Investigator through participant interview and review of medical history.
* Participants must have a prior HS treatment history consistent with the following:

  * For the biologic and immunosuppressive small molecule-naïve subgroup, participants must have no history of treatment with any approved or investigational biologic therapy or small molecule immunosuppressive therapy with potential efficacy for HS.
  * For the biologic and immunosuppressive small molecule-experienced subgroup, participants must have a history of treatment with at least 1 biologic or immunosuppressive small molecule therapy with potential efficacy for HS.

Exclusion Criteria:

* Participants are excluded from the study if any of the following criteria apply:
* Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with assessment of HS.
* History of systemic hypersensitivity or anaphylaxis to any biologic therapy
* History of recurrent or recent serious infection
* Known history of or suspected significant current immunosuppression
* History of solid organ transplant or stem cell transplant.
* History of splenectomy
* History of malignancy or suspicion of malignancy within 5 years prior to the Screening Visit (except for in situ cervical carcinoma that has been treated by surgery and completely cured, or basal cell carcinoma or squamous cell carcinoma that has been excised and completely cured)
* History within the 2 years prior to Baseline Visit of prescription drug or substance abuse, including alcohol, considered significant by the Investigator.
* Any medical or psychiatric condition which, in the opinion of the Investigator could be considered uncontrolled, unstable, or likely to progress in a clinically relevant manner and may present an unreasonable risk to the study participants as a result of his/her participation in this clinical study, may make participant's participation unreliable, or may interfere with study assessments.
* Any other medical condition or severe, concomitant illness, including psychiatric illness and substance abuse, that may present an unreasonable risk to the study participants, make participants unreliable, or may interfere with study assessments.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it's running

• Cahaba Dermatology & Skin Health Center- Site Number : 8400004
  Birmingham, Alabama, United States Recruiting
• Florida International Research Center- Site Number : 8400002
  Miami, Florida, United States Recruiting
• Investigational Site Number : 1240002
  Peterborough, Ontario, Canada Recruiting
• Investigational Site Number : 1240006
  Richmond Hill, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Trial Transparency email recommended (Toll free for US & Canada)
• Email: Contact-US@sanofi.com
• Phone: 800-633-1610

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human study of SAR447971

  This study tests SAR447971 against placebo in healthy adults and in people with hidradenitis suppurativa to see how the drug behaves and whether it is safe.

  Recruiting Phase 1 Sanofi · Leiden · NCT07629336

• Tolebrutinib in real-world MS care for patients treated by clinicians

  This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.

  Recruiting Sanofi · Marina, Abu Dhabi Emirate · NCT07898371

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Rilzabrutinib in adults with severe kidney impairment vs. normal kidney function

  This study tests how rilzabrutinib behaves in the body and its safety in adults with severe kidney impairment compared to healthy adults.

  Recruiting Phase 1 Sanofi · Hialeah, Florida · NCT07853131

• RSV+HMPV protein shot for adults 60 and older

  A single shot of a two-virus vaccine is being tested in adults 60+ to see if it can prevent RSV and hMPV infections compared with placebo.

  Recruiting at 21 sites Phase 2 Sanofi · Bruse, Australian Capital Territory and 20 other locations · NCT07810010

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.